Cardiovascular risk in pediatric-onset rheumatological diseases

Arthritis Research and Therapy

Volumn 15, Issue 3, 2013, Pages

  Barsalou, Julie ^a   Bradley, Timothy J ^a,b   Silverman, Earl D ^a,b,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; AUTOANTIBODY; AZATHIOPRINE; C PEPTIDE; C REACTIVE PROTEIN; CORTICOSTEROID; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA INTERFERON; GLYCERYL TRINITRATE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INSULIN; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUPUS ANTICOAGULANT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPID ANTIBODY; PREDNISONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EXERCISE; FAMILY HISTORY; FLOW MEDIATED DILATATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; JUVENILE DERMATOMYOSITIS; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LIPID BLOOD LEVEL; LUPUS ERYTHEMATOSUS NEPHRITIS; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBESITY; ONSET AGE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PEDIATRIC ONSET SYSTEMIC LUPUS ERYTHEMATOSUS; PEDIATRICS; PREVALENCE; PROSPECTIVE STUDY; PROTEINURIA; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; RHEUMATIC DISEASE; RISK FACTOR; SEDENTARY LIFESTYLE; SIDE EFFECT; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION; WEIGHT GAIN; ADULT; CHILD;

ADULT; AGE OF ONSET; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHILD; HUMANS; RHEUMATIC DISEASES; RISK FACTORS;

EID: 84878622014     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4212     Document Type: Review

References (127)

1. Roifman I, Beck PL, Anderson TJ, Eisenberg MJ, Genest J. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol 2011, 27:174-182. 10.1016/j.cjca.2010.12.040, 21459266.
2. Cines D B, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91:3527-3561.
3. Juonala M, Kahonen M, Laitinen T, Hutri-Kahonen N, Jokinen E, Taittonen L, Pietikainen M, Helenius H, Viikari JS, Raitakari OT. Effect of age and sex on carotid intima-media thickness, elasticity and brachial endothelial function in healthy adults: the cardiovascular risk in Young Finns Study. Eur Heart J 2008, 29:1198-1206. 10.1093/eurheartj/ehm556, 18079136.
4. Benjamin EJ, Larson MG, Keyes MJ, Mitchell GF, Vasan RS, Keaney JF, Lehman BT, Fan S, Osypiuk E, Vita JA. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 2004, 109:613-619. 10.1161/01.CIR.0000112565.60887.1E, 14769683.
5. Bots ML, Grobbee DE, Hofman A, Witteman JC. Common carotid intima-media thickness and risk of acute myocardial infarction: the role of lumen diameter. Stroke 2005, 36:762-767. 10.1161/01.STR.0000158924.71069.94, 15746451.
6. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115:459-467. 10.1161/CIRCULATIONAHA.106.628875, 17242284.
7. Nguyen QM, Toprak A, Xu JH, Srinivasan SR, Chen W, Berenson GS. Progression of segment-specific carotid artery intima-media thickness in young adults (from the Bogalusa Heart Study). Am J Cardiol 2011, 107:114-119. 10.1016/j.amjcard.2010.08.054, 21146698.
8. Aatola H, Hutri-Kahonen N, Juonala M, Viikari JS, Hulkkonen J, Laitinen T, Taittonen L, Lehtimaki T, Raitakari OT, Kahonen M. Lifetime risk factors and arterial pulse wave velocity in adulthood: the cardiovascular risk in young Finns study. Hypertension 2010, 55:806-811. 10.1161/HYPERTENSIONAHA.109.145102, 20083727.
9. Tsuchikura S, Shoji T, Kimoto E, Shinohara K, Hatsuda S, Koyama H, Emoto M, Nishizawa Y. Central versus peripheral arterial stiffness in association with coronary, cerebral and peripheral arterial disease. Atherosclerosis 2010, 211:480-485. 10.1016/j.atherosclerosis.2010.03.037, 20430390.
10. Urbina EM, Williams RV, Alpert BS, Collins RT, Daniels SR, Hayman L, Jacobson M, Mahoney L, Mietus-Snyder M, Rocchini A, Steinberger J, McCrindle B, American Heart Association Atherosclerosis Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension 2009, 54:919-950. 10.1161/HYPERTENSIONAHA.109.192639, 19729599, American Heart Association Atherosclerosis Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young.
11. Tucker L. Review: Making the diagnosis of systemic lupus erythematosus in children and adolescents. Lupus 2007, 16:546-549. 10.1177/0961203307078068, 17711886.
12. Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2010, 30:1014-1026. 10.1161/ATVBAHA.109.198424, 20150560.
13. Urowitz MB, Gladman D, Ibanez D, Fortin P, Sanchez-Guerrero J, Bae S, Clarke A, Bernatsky S, Gordon C, Hanly J, Wallace D, Isenberg D, Ginzler E, Merrill J, Alarcon G, Steinsson K, Petri M, Dooley MA, Bruce I, Manzi S, Khamashta M, Ramsey-Goldman R, Zoma A, Sturfelt G, Nived O, Maddison P, Font J, van Vollenhoven R, Aranow C, Kalunian K, Stoll T, Buyon J. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus 2007, 16:731-735. 10.1177/0961203307081113, 17728367.
14. Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, Katz P, Criswell LA, Yelin E. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum 2009, 61:13-20. 2875186, 19116979.
15. Hersh AO, Trupin L, Yazdany J, Panopalis P, Julian L, Katz P, Criswell LA, Yelin E. Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus. Arthritis Care Res 2010, 62:1152-1159. 10.1002/acr.20179, 20235215.
16. California Department of Health Statistics Death Statistics Data Table - Leading Causes of Female Deaths by Age and Race/Ethnic Group and Rates for All Races Combined 2010, California, USA: California Department of Health Statistics, California Department of Health Statistics.
17. Boros CA, Bradley TJ, Cheung MM, Bargman JM, Russell JL, McCrindle BW, Adeli K, Hamilton J, Silverman ED. Early determinants of atherosclerosis in paediatric systemic lupus erythematosus. Clin Exp Rheumatol 2011, 29:575-581.
18. Bowser CS, Kumar S, Salciccioli L, Kutlin A, Lazar J, Rahim I, Suss A, Kohlhoff S, Hammerschlag MR, Moallem HJ. Absence of Chlamydia pneumoniae and signs of atherosclerotic cardiovascular disease in adolescents with systemic lupus erythematosus. Pediatr Cardiol 2008, 29:545-551. 10.1007/s00246-007-9131-x, 18080155.
19. Falaschi F, Ravelli A, Martignoni A, Migliavacca D, Sartori M, Pistorio A, Perani G, Martini A. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2000, 43:1405-1409. 10.1002/1529-0131(200006)43:6<1405::AID-ANR26>3.0.CO;2-V, 10857801.
20. Huang YL, Chung HT, Chang CJ, Yeh KW, Chen LC, Huang JL. Lymphopenia is a risk factor in the progression of carotid intima-media thickness in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2009, 60:3766-3775. 10.1002/art.25019, 19950269.
21. Nascif AK, Hilario MO, Terreri MT, Ajzen SA, D'Almeida V, Plavnik FL, de Jesus Christofalo DM. Endothelial function analysis and atherosclerotic risk factors in adolescents with systemic lupus erythematosus. Int J Adolesc Med Health 2007, 19:497-505.
22. Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, Mieszkalski KL, Ilowite NT, Eberhard A, Levy DM, Kimura Y, von Scheven E, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed A, Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intimamedia thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum 2009, 60:1496-1507. 10.1002/art.24469, 2770725, 19404953, Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators.
23. Soep JB, Mietus-Snyder M, Malloy MJ, Witztum JL, von Scheven E. Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus. Arthritis Rheum 2004, 51:451-457. 10.1002/art.20392, 15188333.
24. Oren A, Vos LE, Uiterwaal CS, Grobbee DE, Bots ML. Cardiovascular risk factors and increased carotid intima-media thickness in healthy young adults: the Atherosclerosis Risk in Young Adults (ARYA) Study. Arch Intern Med 2003, 163:1787-1792. 10.1001/archinte.163.15.1787, 12912713.
25. Jourdan C, Wuhl E, Litwin M, Fahr K, Trelewicz J, Jobs K, Schenk JP, Grenda R, Mehls O, Tröger J, Schaefer F. Normative values for intima-media thickness and distensibility of large arteries in healthy adolescents. J Hypertens 2005, 23:1707-1715. 10.1097/01.hjh.0000178834.26353.d5, 16093916.
26. Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kimura Y, von Scheven E, Silverman E, Bowyer SL, Punaro M, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed AM, Provenzale J, Thompson SD, Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum 2012, 64:285-296. 10.1002/art.30645, 22031171, Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators.
27. Ilowite NT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988, 31:859-863. 10.1002/art.1780310706, 3134897.
28. Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997, 6:533-539. 10.1177/096120339700600610, 9256312.
29. Tyrrell PN, Beyene J, Benseler SM, Sarkissian T, Silverman ED. Predictors of lipid abnormalities in children with new-onset systemic lupus erythematosus. J Rheumatol 2007, 34:2112-2119.
30. Ardoin SP, Schanberg LE, Sandborg C, Yow E, Barnhart HX, Mieszkalski K, Ilowite NT, von Scheven E, Eberhard A, Levy DM, Kimura Y, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung LK, Imundo L, Soep JB, Reed AM, APPLE Investigators Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort. Lupus 2010, 19:1315-1325. 10.1177/0961203310373937, 20861207, APPLE Investigators.
31. Sarkissian T, Beyene J, Feldman B, McCrindle B, Silverman ED. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum 2007, 56:631-638. 10.1002/art.22332, 17265498.
32. Sarkissian T, Beyenne J, Feldman B, Adeli K, Silverman E. The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. Arthritis Rheum 2006, 54:1283-1290. 10.1002/art.21748, 16575849.
33. Sabio JM, Zamora-Pasadas M, Jimenez-Jaimez J, Albadalejo F, Vargas-Hitos J, Rodriguez del Aguila MD, Hidalgo-Tenorio C, Gonzalez-Gay MA, Jimenez-Alonso J. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 2008, 17:849-859. 10.1177/0961203308093554, 18755869.
34. El Magadmi M, Ahmad Y, Turkie W, Yates AP, Sheikh N, Bernstein RM, Durrington PN, Laing I, Bruce IN. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 2006, 33:50-56.
35. Zeng YJ, Zeng FQ, Dai L, Yang C, Lin BZ, Zheng DH, Liu D, Yan L, Ren M, Cheng H. Characteristics and risk factors for hyperglycemia in Chinese female patients with systemic lupus erythematosus. Lupus 2010, 19:1344-1350. 10.1177/0961203310375439, 20693192.
36. Posadas-Romero C, Torres-Tamayo M, Zamora-Gonzalez J, Aguilar-Herrera BE, Posadas-Sanchez R, Cardoso-Saldana G, Ladron de Guevara G, Solis-Vallejo E, El Hafidi M. High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. Arthritis Rheum 2004, 50:160-165. 10.1002/art.11472, 14730612.
37. Steinberg GR, Michell BJ, van Denderen BJ, Watt MJ, Carey AL, Fam BC, Andrikopoulos S, Proietto J, Gorgun CZ, Hotamisligil GS, Febbraio MA, Kay TW, Kemp BE. Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 2006, 4:465-474. 10.1016/j.cmet.2006.11.005, 17141630.
38. Emanuela F, Grazia M, Marco de R, Maria Paola L, Giorgio F, Marco B. Inflammation as a link between obesity and metabolic syndrome. J Nutr Metab 2012, 2012:476380. 3317136, 22523672.
39. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?. Eur J Clin Invest 2009, 39:81-93. 10.1111/j.1365-2362.2008.02067.x, 19200161.
40. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 2002, 81:87-100. 10.1097/00005792-200203000-00001, 11889410.
41. Cortes S, Chambers S, Jeronimo A, Isenberg D. Diabetes mellitus complicating systemic lupus erythematosus - analysis of the UCL lupus cohort and review of the literature. Lupus 2008, 17:977-980. 10.1177/0961203308091539, 18852220.
42. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senécal JL. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331-2337. 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I, 11665973.
43. Weiss N, Keller C, Hoffmann U, Loscalzo J. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 2002, 7:227-239. 10.1191/1358863x02vm428ra, 12553746.
44. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G, Koller A. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2003, 23:418-424. 10.1161/01.ATV.0000061735.85377.40, 12615666.
45. Au-Yeung KK, Woo CW, Sung FL, Yip JC, Siow YL, O K. Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res 2004, 94:28-36. 10.1161/01.RES.0000108264.67601.2C, 14630727.
46. Kalra DK. Homocysteine and cardiovascular disease. Curr Atheroscler Rep 2004, 6:101-106. 10.1007/s11883-004-0097-3, 15023293.
47. Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 2009, 40:1365-1372. 10.1161/STROKEAHA.108.529503, 19228852.
48. Narshi CB, Giles IP, Rahman A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus?. Lupus 2011, 20:5-13. 10.1177/0961203310382429, 21138982.
49. do Prado R, D'Almeida VM, Guerra-Shinohara E, Galdieri LC, Terreri MT, Hilario MO. Increased concentration of plasma homocysteine in children with systemic lupus erythematosus. Clin Exp Rheumatol 2006, 24:594-598.
50. Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, Butfiloski EJ, Sobel ES, Reeves WH, Segal MS. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007, 56:3759-3769. 10.1002/art.23035, 17968925.
51. Thacker SG, Berthier CC, Mattinzoli D, Rastaldi MP, Kretzler M, Kaplan MJ. The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010, 185:4457-4469. 10.4049/jimmunol.1001782, 2978924, 20805419.
52. Li J, Fu Q, Cui H, Qu B, Pan W, Shen N, Bao C. Interferon-alpha priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-alpha and atherosclerosis in lupus. Arthritis Rheum 2011, 63:492-502. 10.1002/art.30165, 21280004.
53. Goossens P, Gijbels MJ, Zernecke A, Eijgelaar W, Vergouwe MN, van der Made I, Vanderlocht J, Beckers L, Buurman WA, Daemen MJ, Daemen MJ, Kalinke U, Weber C, Lutgens E, de Winther MP. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab 2010, 12:142-153. 10.1016/j.cmet.2010.06.008, 20674859.
54. Lood C, Amisten S, Gullstrand B, Jonsen A, Allhorn M, Truedsson L, Sturfelt G, Erlinge D, Bengtsson AA. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 2010, 116:1951-1957. 10.1182/blood-2010-03-274605, 20538795.
55. Somers EC, Zhao W, Lewis EE, Wang L, Wing JJ, Sundaram B, Kazerooni EA, McCune WJ, Kaplan MJ. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One 2012, 7:e37000. 10.1371/journal.pone.0037000, 3351452, 22606325.
56. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723. 10.1084/jem.20021553, 2193846, 12642603.
57. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JP, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GD, Gudnason V. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008, 5(4):e78. 10.1371/journal.pmed.0050078, 2288623, 18399716.
58. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772. 10.1161/01.CIR.101.15.1767, 10769275.
59. Svenungsson E, Fei GZ, Jensen-Urstad K, de Faire U, Hamsten A, Frostegard J. TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 2003, 12:454-461. 10.1191/0961203303lu412oa, 12873047.
60. Asanuma Y, Chung CP, Oeser A, Shintani A, Stanley E, Raggi P, Stein CM. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006, 33:539-545.
61. Chung CP, Oeser A, Solus J, Avalos I, Gebretsadik T, Shintani A, Linton MF, Fazio S, Stein CM. Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus. J Rheumatol 2007, 34:1849-1854.
62. Rua-Figueroa I, Arencibia-Mireles O, Elvira M, Erausquin C, Ojeda S, Francisco F, Naranjo A, Rodriguez-Gallego C, Garcia-Laorden I, Rodriguez-Perez J, Rodríguez-Lozano C. Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study. Ann Rheum Dis 2010, 69:1136-1139. 10.1136/ard.2008.104349, 19687018.
63. Sabio JM, Vargas-Hitos J, Zamora-Pasadas M, Mediavilla JD, Navarrete N, Ramirez A, Hidalgo-Tenorio C, Jaimez L, Martin J, Jimenez-Alonso J. Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol 2009, 36:2204-2211. 10.3899/jrheum.081253, 19723903.
64. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406. 10.1056/NEJMoa035471, 14681505.
65. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737. 10.1001/jama.291.14.1730, 15082700.
66. Chung CP, Long AG, Solus JF, Rho YH, Oeser A, Raggi P, Stein CM. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus 2009, 18:799-806. 10.1177/0961203309103582, 2707942, 19578104.
67. Reynolds HR, Buyon J, Kim M, Rivera TL, Izmirly P, Tunick P, Clancy RM. Association of plasma soluble E-selectin and adiponectin with carotid plaque in patients with systemic lupus erythematosus. Atherosclerosis 2010, 210:569-574. 10.1016/j.atherosclerosis.2009.12.007, 20044088.
68. McMahon M, Skaggs BJ, Sahakian L, Grossman J, Fitzgerald J, Ragavendra N, Charles-Schoeman C, Chernishof M, Gorn A, Witztum JL, Wong WK, Weisman M, Wallace DJ, La Cava A, Hahn BH. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis 2011, 70:1619-1624. 10.1136/ard.2010.142737, 3147230, 21670088.
69. Baker JF, Morales M, Qatanani M, Cucchiara A, Nackos E, Lazar MA, Teff K, von Feldt JM. Resistin levels in lupus and associations with disease-specific measures, insulin resistance, and coronary calcification. J Rheumatol 2011, 38:2369-2375. 10.3899/jrheum.110237, 21885493.
70. Al M, Ng L, Tyrrell P, Bargman J, Bradley T, Silverman E. Adipokines as novel biomarkers in paediatric systemic lupus erythematosus. Rheumatology (Oxford) 2009, 48:497-501.
71. Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U, Witztum JL, Frostegard J. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001, 104:1887-1893. 10.1161/hc4101.097518, 11602489.
72. Sule S, Fivush B, Neu A, Furth S. Increased risk of death in pediatric and adult patients with ESRD secondary to lupus. Pediatr Nephrol 2011, 26:93-98. 10.1007/s00467-010-1640-9, 2992078, 20890767.
73. Rinat C, Becker-Cohen R, Nir A, Feinstein S, Shemesh D, Algur N, Ben Shalom E, Farber B, Frishberg Y. A comprehensive study of cardiovascular risk factors, cardiac function and vascular disease in children with chronic renal failure. Nephrol Dial Transplant 2010, 25:785-793. 10.1093/ndt/gfp570, 19934091.
74. Litwin M, Wuhl E, Jourdan C, Niemirska A, Schenk JP, Jobs K, Grenda R, Wawer ZT, Rajszys P, Mehls O, Schaefer F. Evolution of large-vessel arteriopathy in paediatric patients with chronic kidney disease. Nephrol Dial Transplant 2008, 23:2552-2557. 10.1093/ndt/gfn083, 18344239.
75. Tucker PS, Dalbo VJ, Han T, Kingsley MI. Clinical and research markers of oxidative stress in chronic kidney disease. Biomarkers 2013, 18:103-115. 10.3109/1354750X.2012.749302, 23339563.
76. Luksha N, Luksha L, Carrero JJ, Hammarqvist F, Stenvinkel P, Kublickiene K. Impaired resistance artery function in patients with end-stage renal disease. Clin Sci 2011, 120:525-536. 10.1042/CS20100277, 21222655.
77. Yilmaz MI, Stenvinkel P, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Çakar M, Altun B, Yenicesu M, Carrero JJ. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant 2011, 26:3537-3543. 10.1093/ndt/gfr081, 21378154.
78. Moody W E, Edwards NC, Madhani M, Chue CD, Steeds RP, Ferro CJ, Townend JN. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association?. Atherosclerosis 2012, 223:86-94. 10.1016/j.atherosclerosis.2012.01.043, 22349087.
79. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Internal Med 2004, 140:9-17. 10.7326/0003-4819-140-1-200401060-00006, 14706967.
80. Han C, Robinson DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006, 33:2167-2172.
81. Nurmohamed MT. Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 2009, 8:663-667. 10.1016/j.autrev.2009.02.015, 19393192.
82. Gorska A, Rutkowska-Sak L, Musiej-Nowakowska E, Chlabicz S, Gorski S. [Nailfold videocapillaroscopy - a useful tool for screening patients with juvenile idiopathic arthritis at the risk of development of premature atherosclerosis]. Postepy Hig Med Dosw (Online) 2010, 64:296-302.
83. Pietrewicz E, Urban M. [Early atherosclerosis changes in children with juvenile idiopathic arthritis]. Pol Merkur Lekarski 2007, 22:211-214.
84. Urban M, Pietrewicz E, Gorska A, Szczepanski W, Baran M. [Correlation between intima-media thickness in carotid artery and markers of epithelial cell dysfunction in patients with juvenile idiopathic arthritis]. Med Wieku Rozwoj 2009, 13:277-282.
85. Argyropoulou MI, Kiortsis DN, Daskas N, Xydis V, Mavridis A, Efremidis SC, Siamopoulou A. Distensibility and pulse wave velocity of the thoracic aorta in patients with juvenile idiopathic arthritis: an MRI study. Clin Exp Rheumatol 2003, 21:794-797.
86. Breda L, Di Marzio D, Giannini C, Gaspari S, Nozzi M, Scarinci A, Chiarelli F, Mohn A. Relationship between inflammatory markers, oxidant-antioxidant status and intima-media thickness in prepubertal children with juvenile idiopathic arthritis. Clin Res Cardiol 2013, 102:63-71. 10.1007/s00392-012-0496-3, 22885951.
87. Vlahos AP, Theocharis P, Bechlioulis A, Naka KK, Vakalis K, Papamichael ND, Alfantaki S, Gartzonika K, Mavridis A, Michalis LK, Siamopoulou A. Changes in vascular function and structure in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011, 63:1736-1744. 10.1002/acr.20613, 21905249.
88. Honkanen VE, Pelkonen P, Konttinen YT, Mussalo-Rauhamaa H, Lehto J, Westermarck T. Serum cholesterol and vitamins A and E in juvenile chronic arthritis. Clin Exp Rheumatol 1990, 8:187-191.
89. Marangoni RG, Hayata AL, Borba EF, Azevedo PM, Bonfa E, Schainberg CG. Decreased high-density lipoprotein cholesterol levels in polyarticular juvenile idiopathic arthritis. Clinics (Sao Paulo) 2011, 66:1549-1552. 10.1590/S1807-59322011000900007, 3164402, 22179157.
90. Musiej-Nowakowska E, Zawadzka F, Wesolowska H, Mikolajew M. Serum lipid concentrations in juvenile rheumatoid arthritis. Acta Univ Carol Med (Praha) 1991, 37:46-49.
91. Tselepis AD, Elisaf M, Besis S, Karabina SA, Chapman MJ, Siamopoulou A. Associat ion of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity. Arthritis Rheum 1999, 42:373-383. 10.1002/1529-0131(199902)42:2<373::AID-ANR21>3.0.CO;2-3, 10025933.
92. Ilowite NT, Samuel P, Beseler L, Jacobson MS. Dyslipoproteinemia in juvenile rheumatoid arthritis. J Pediatr 1989, 114:823-826. 10.1016/S0022-3476(89)80148-9, 2715897.
93. Bakkaloglu A, Kirel B, Ozen S, Saatci U, Besbas N. Plasma lipids and lipoproteins in juvenile chronic arthritis. Clin Rheumatol 1996, 15:341-345. 10.1007/BF02230355, 8853166.
94. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A, PRINTO, PRCSG Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367:2385-2395. 10.1056/NEJMoa1112802, 23252525, PRCSG.
95. Goncalves M, D'Almeida V, Guerra-Shinohara EM, Galdieri LC, Len CA, Hilario MO. Homocysteine and lipid profile in children with Juvenile Idiopathic Arthritis. Pediatr Rheumatol Online J 2007, 5:2. 10.1186/1546-0096-5-2, 1869026, 17550630.
96. Huemer M, Fodinger M, Huemer C, Sailer-Hock M, Falger J, Rettenbacher A, Bernecker M, Artacker G, Kenzian H, Lang T, Stöckler-Ipsiroglu S. Hyperhomocysteinemia in children with juvenile idiopathic arthritis is not influenced by methotrexate treatment and folic acid supplementation: a pilot study. Clin Exp Rheumatol 2003, 21:249-255.
97. Huemer M, Huemer C, Ulmer H, Crone J, Fodinger M, Falger J, Sailer-Hock M. No evidence for hyperhomocysteinemia or increased prevalence of genetic polymorphisms in the homocysteine pathway in patients with moderate juvenile idiopathic arthritis. J Rheumatol 2005, 32:170-174.
98. Cantarini L, Simonini G, Fioravanti A, Generoso M, Bacarelli MR, Dini E, Galeazzi M, Cimaz R. Circulating levels of the adipokines vaspin and omentin in patients with juvenile idiopathic arthritis, and relation to disease activity. Clin Exp Rheumatol 2011, 29:1044-1048.
99. Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010, 20:143-148. 10.1016/j.tcm.2010.12.002, 21742269.
100. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin, a novel ad ipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011, 408:339-343. 10.1016/j.bbrc.2011.04.039, 21514279.
101. Elwakkad AS, Said RN, Muhammad SI, Saleh MT, Elhamshary A. Role for leptin and prolactin in human juvenile rheumatic diseases. Pak J Biol Sci 2007, 10:1984-1989.
102. Perfetto F, Tarquini R, Simonini G, Bindi G, Mancuso F, Guiducci S, Matucci-Cerinic M, Falcini F. Circulating leptin levels in juvenile idiopathic arthritis: a marker of nutritional status?. Ann Rheum Dis 2005, 64:149-152. 10.1136/ard.2003.019398, 1755198, 15608316.
103. Caetano MC, Sarni RO, Terreri MT, Ortiz TT, Pinheiro M, de Souza FI, Hilario MO. Excess of adiposity in female children and adolescents with juvenile idiopathic arthritis. Clin Rheumatol 2012, 31:967-971. 10.1007/s10067-012-1947-y, 22362257.
104. Tisseverasinghe A, Bernatsky S, Pineau CA. Arterial events in persons with derma tomyositis and polymyositis. J Rheumatol 2009, 36:1943-1946. 10.3899/jrheum.090061, 19648306.
105. Zoller B, Li X, Sundquist J, Sundquist K. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PLoS One 2012, 7:e33442. 10.1371/journal.pone.0033442, 3306397, 22438933.
106. Eimer MJ, Brickman WJ, Seshadri R, Ramsey-Goldman R, McPherson DD, Smulevitz B, Stone NJ, Pachman LM. Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis. J Pediatr 2011, 159:795-801. 10.1016/j.jpeds.2011.05.015, 3193560, 21784434.
107. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Carrick DM, Sebring N, O'Hanlon TP, Ruiz-Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, Rider LG, Childhood Myositis Heterogeneity Study Group Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 2008, 87:70-86. 10.1097/MD.0b013e31816bc604, 2674585, 18344805, Childhood Myositis Heterogeneity Study Group.
108. McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, Pilkington CA. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) - clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006, 45:1255-1260. 10.1093/rheumatology/kel099, 16567354.
109. Verma S, Singh S, Bhalla AK, Khullar M. Study of subcutaneous fat in children with juvenile dermatomyositis. Arthritis Rheum 2006, 55:564-568. 10.1002/art.22108, 16874777.
110. Coyle K, Rother KI, Weise M, Ahmed A, Miller FW, Rider LG. Metabolic abnormalitie s and cardiovascular risk factors in children with myositis. J Pediatr 2009, 155:882-887. 10.1016/j.jpeds.2009.06.009, 2809424, 19643439.
111. Baechler EC, Bilgic H, Reed AM. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 2011, 13:249. 10.1186/ar3531, 3334651, 22192711.
112. Li S, Chen W, Srinivasan SR, Bond MG, Tang R, Urbina EM, Berenson GS. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 2003, 290:2271-2276. 10.1001/jama.290.17.2271, 14600185.
113. Raitakari OT, Juonala M, Kahonen M, Taittonen L, Laitinen T, Maki-Torkko N, Jarvisalo MJ, Uhari M, Jokinen E, Ronnemaa T, Akerblom HK, Viikari JS. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003, 290:2277-2283. 10.1001/jama.290.17.2277, 14600186.
114. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006, 114:2710-2738. 10.1161/CIRCULATIONAHA.106.179568, 17130340.
115. Hodis HN, Quismorio FP, Wickham E, Blankenhorn DH. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993, 20:661-665.
116. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994, 96:254-259. 10.1016/0002-9343(94)90151-1, 8154514.
117. Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000, 27:2142-2145.
118. Penn SK, Kao AH, Schott LL, Elliott JR, Toledo FG, Kuller L, Manzi S, Wasko MC. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2010, 37:1136-1142. 10.3899/jrheum.090994, 3457696, 20436082.
119. Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, Choy E, Ostor AJK, Edwards CJ. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 2011, 50:518-531. 10.1093/rheumatology/keq316, 21071477.
120. Major AS, Fazio S, Linton MF. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 2002, 22:1892-1898. 10.1161/01.ATV.0000039169.47943.EE, 12426221.
121. Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L, Taleb S, Van Vre E, Esposito B, Vilar J, Sirvent J, Van Snick J, Tedgui A, Tedder TF, Mallat Z. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 2010, 207:1579-1587. 10.1084/jem.20100155, 2916123, 20603314.
122. Bulgarelli A, Martins Dias AA, Caramelli B, Maranhao RC. Treatment with methotrex ate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol 2012, 59:308-314. 10.1097/FJC.0b013e318241c385, 22113347.
123. Toloza SM, Uribe AG, McGwin G, Alarcon GS, Fessler BJ, Bastian HM, Vila LM, Wu R, Shoenfeld Y, Roseman JM, Reveille JD, LUMINA Study Group Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004, 50:3947-3957. 10.1002/art.20622, 15593203, LUMINA Study Group.
124. van Leuven SI, Mendez-Fernandez YV, Wilhelm AJ, Wade NS, Gabriel CL, Kastelein JJ, Stroes ES, Tak PP, Major AS. Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr-/- mice. Ann Rheum Dis 2012, 71:408-414. 10.1136/annrheumdis-2011-200071, 3306213, 21953346.
125. van Leuven SI, van Wijk DF, Volger OL, de Vries JP, van der Loos CM, de Kleijn DV, Horrevoets AJ, Tak PP, van der Wal AC, de Boer OJ, Pasterkamp G, Hayden MR, Kastelein JJ, Stroes ES. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis 2010, 211:231-236. 10.1016/j.atherosclerosis.2010.01.043, 20202636.
126. Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE, Gardner-Medwin J, Wilkinson N, Riley P, Tizard J, Armon K, Sinha MD, Ioannou Y, Archer N, Bailey K, Davidson J, Baildam EM, Cleary G, McCann LJ, Beresford MW, UK Juvenile-Onset Systemic Lupus Erythematosus Study Group Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum 2012, 64:2356-2365. 10.1002/art.34410, 22294381, UK Juvenile-Onset Systemic Lupus Erythematosus Study Group.
127. Hasija R, Pistorio A, Ravelli A, Demirkaya E, Khubchandani R, Guseinova D, Malattia C, Canhao H, Harel L, Foell D, Wouters C, De Cunto C, Huemer C, Kimura Y, Mangge H, Minetti C, Nordal EB, Philippet P, Garozzo R, Martini A, Ruperto N, Pediatric Rheumatology International Trials Organization Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. Arthritis Rheum 2011, 63:3142-3152. 10.1002/art.30475, 21647864, Pediatric Rheumatology International Trials Organization.